Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Carvedilol

Drug Profile

Carvedilol

Alternative Names: Artist; Aucardic; BM 14190; Cardiol; Carloc; Caslot; Coreg; Coropres; Dilatrend; Dilbloc; Dimitone; DQ 2466; Eucardic; Kredex; Querto; SKF 105517

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Columbia Northwest Pharmaceuticals; Daiichi Sankyo Company
  • Class Antihypertensives; Carbazoles; Ethanolamines; Heart failure therapies; Ischaemic heart disorder therapies; Phenyl ethers; Propanolamines; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists; Antioxidants; Beta-adrenergic receptor antagonists; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Angina pectoris; Heart failure; Hypertension
  • No development reported Atrial fibrillation
  • Discontinued Arrhythmias; Ischaemic heart disorders; Myocardial infarction; Post-traumatic stress disorders; Reperfusion injury

Most Recent Events

  • 10 Jul 2019 No development reported - Registered for Atrial fibrillation in Japan (PO) after August 2015
  • 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
  • 25 Mar 2015 Ranbaxy Laboratories has been acquired by Sun Pharmaceutical Industries
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top